On January 13, 2015, Huanyu Dakang Medical News pharmaceutical giant Squibb Company ushered in a good start in 2015. The anti-cancer immunotherapy drug nivolumab developed by the company was approved last month under the trade name of Opdivo. In the first month of 2015, Opdivo heard good news again. In a comparative clinical study of kwayar cutar huhu conducted by Squibb, Opdivo obtained new positive research data. In this clinical study involving 272 lung cancer patients, the researchers compared the efficacy of Opdivo with the current clinical standard therapy docetaxel, and the results proved the obvious advantage of this drug in the overall survival rate of patients. Reached the primary end point expected by previous researchers.
Opdivo is currently the most popular PD-1 drug. PD-1 is a cell cycle checkpoint protein. Its runaway causes tumo cells to escape immune monitoring in the body. According to the decision made by the FDA last month, Opdivo was approved for the treatment of melanoma (related reading: FDA approved Squibb PD-1 inhibitor Nivolumab (Opdivo) three months in advance, the same price as Keytruda) Similar drugs in this field are Keytruda from Merck. The results of Squibb ’s clinical research have made Opdivo the first PD-1 drug to treat lung cancer. More importantly, this result will help Squibb to lead its competitors in PD-1 drug research. Pharmaceutical companies currently active in this area include biomedical giants such as Merck, Roche and AstraZeneca.
Squibb ya bayyana cewa kamfanin ya gabatar da aikace-aikacen Opdivo don maganin alamun ciwon huhu ga FDA da hukumar kula da magunguna ta EU. Tabbas, Kamfanin Squibb mai burin ba zai gamsu da kansa kawai da ciwon huhu da melanoma ba. A gaskiya ma, Squibb a halin yanzu yana gudanar da bincike fiye da 35 na Opdivo kadai ko a hade tare da wasu magunguna don magance nau'in ciwon daji daban-daban. A cewar manazarta, siyar da Opdivo a nan gaba zai kai dalar Amurka biliyan 5.
The cancer immunotherapy research that has emerged in recent years has brought new hope for humans to conquer the disease of cancer. Almost all biomedical giants are planning in this field, hoping to share a cake. However, it is not yet known who will be the biggest winner in this technological revolution.
Cikakken rahoton Turanci:
Bristol-Myers Squibb's ($ Kø) tsayayye na immuno-o ncology miyagun ƙwayoyi nivolumab, wanda aka amince da shi a watan da ya gabata kamar yadda Opdivo, ya samu gagarumar nasara a gwajin ciwon huhu na ƙarshen zamani, yana ƙarfafa tsammanin tallace-tallace don maganin pio neering.
A cikin binciken marasa lafiya 272 da ke nuna Opdivo a kan daidaitaccen mai kashe cutar kansa docetaxel, Bristol-Myers miyagun ƙwayoyi ya nuna irin wannan kyakkyawan rayuwa gabaɗaya idan aka kwatanta da ƙungiyar da ke kula da ikon da ta kai matakin ƙarshe kafin lokacin tsarawa, wanda ke jagorantar bayanan gwaji na kwamitin. a daina binciken da wuri. Bristol-Myers yanzu yana gayyatar marasa lafiya a cikin rukunin docetaxel don shiga cikin Opdivo ta hanyar binciken fadada lakabin.
An ƙera maganin Bristol-Myers don ƙaddamar da wani hari na rigakafi akan ciwace-ciwacen daji ta hanyar toshe hanyar da ake kira PD-1, wanda, ba a kula da shi ba, yana ba da damar kwayoyin cutar kansa su wuce ba tare da gano su ba ta hanyar kariyar jiki. Kamar Merck's ($ MRK) mai kama da Keytruda, Opdivo ya sami amincewar FDA a bara a matsayin magani ga melanoma, amma magani na Bristol-Myers ya tsaya shi kaɗai a cikin ciwon huhu, saboda nasarar da ta samu na asibiti a karon farko da mai hana PD-1 ya tsara Amfanin tsira daga cutar, in ji kamfanin.
Opdivo’s particular promise in cututtukan daji na kansa marasa kansar has led analysts to pencil it in as the most commercially promising among therapies that block PD-1 and the related PD-L1, putting Bristol-Myers ahead of Merck, Roche ($ RHHBY), AstraZeneca ($ AZN) and others. Analysts figure Opdivo will bring in peak sales of around $ 5 billion, and Leerink’s Seamus Fernandez believes the treatment’s potential in lung cancer will take it as high as $ 7.3 billion by 2020. The entire class of therapies is expected to bring in a bout $ 35 billion a year.
Bristol-Myers ta gabatar da aikace-aikacen kansar huhu a cikin Amurka da Turai don Opdivo a cikin ciwon huhu, yana tsammanin fadada amfani da miyagun ƙwayoyi daga baya a wannan shekara.
Like its competitors, Bristol-Myers has mounted an expansive R & D program for its PD-1 candidate, running more than 35 trials in total that test Opdivo alone or as part of a cocktail in renal cell carcinoma, kansar kai da wuya, glioblastoma, Non-Hodgkin lymphoma and other cancers.
